This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About SIMPONI® (golimumab)

Updated on 15/03/2018

IMMUNOLOGY
SIMPONI indications

A self-injectable biologic treatment

SIMPONI (golimumab) was developed to fit with patient needs and lifestyle, whilst continuing to improve functionality and disease outcomes. It is the first and only subcutaneous anti-TNF therapy with convenient once-monthly dosing licenced for Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Juvenile Idiopathic Arthritis and a 4-weekly dosing schedule for Ulcerative Colitis.1

To learn more please click the options below

SmartJect® features1

Image showing SmartJect features

1. Hidden needle – thin needle automatically deploys (first click), then retracts (second click), so your patients never have to see it.

2. Green safety sleeve – interlock prevents operation until the device is firmly pressed against injection site.

3. Activation button – patients press the raised part of the button to start the injection.

4. Large viewing window – makes it easy to see when the full dose of SIMPONI has been administered.

5. Expiration date – clearly printed on the side of the autoinjector.

6. Easy-to-grip shape – designed with patients in mind, with an easy-to-grip, oval-shaped body.

Important safety information

SIMPONI patient support materialsFind out more

References

  1. SIMPONI Summary of Product Characteristics.
  2. SIMPONI Patient Information Leaflet.

Supporting documentation

SIMPONI 50 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for Pre-filled Syringe | Patient Information Leaflet for Pre-filled Pen

SIMPONI 100 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for Pre-filled Pen

MULT-1246519-0000 | Date of Preparation: March 2018